This is a 3D print of X-ray crystallography dataset 4HJO, the Crystal Structure of the Inactive EGFR Tyrosine Kinase Domain with Erlotinib. 4TRP
“Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through parallel computational and crystallographic studies, we show in the present study that erlotinib also binds the inactive EGFR-TKD conformation, which may have significant implications for its use in EGFR-mutated cancers.”
Inactive EGFR 3D Visualization
Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
Models available in multiple sizes.